William Blair Reaffirms Their Buy Rating on Kadant (KAI)
In a report released today, Ross Sparenblek from William Blair maintained a Buy rating on Kadant (KAI – Research Report). The company's shares closed today at $320.49.
Confident Investing Starts Here:
Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Sparenblek covers the Industrials sector, focusing on stocks such as MSA Safety, SPX, and Mayville Engineering Company. According to TipRanks, Sparenblek has an average return of 12.1% and a 76.00% success rate on recommended stocks.
Kadant has an analyst consensus of Moderate Buy, with a price target consensus of $327.50.
KAI market cap is currently $3.62B and has a P/E ratio of 32.59.
Based on the recent corporate insider activity of 39 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of KAI in relation to earlier this year. Most recently, in March 2025, Thomas Andrew Blanchard, the VP of KAI sold 325.00 shares for a total of $111,016.75.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
28 minutes ago
- Yahoo
Arete initiates CoreWeave and Nebius with preference for Nebius
As previously reported, Arete analyst Andrew Beale initiated coverage of CoreWeave (CRWV) with a Neutral rating and $130 price target. Coreweave and Nebius (NBIS) are neo clouds or artificial intelligence hyperscalers, building new generation GPU- rather than CPU-based cloud services, the analyst tells investors in a research note. The firm says that when including private companies, there are a couple of dozen competitors, with Coreweave having by far the most revenue. Both stocks seem likely to trade on how short of GPU compute investors think the world is, contends Arete. The firm prefers Nebius to Coreweave fundamentally, saying the stock's embedded neo cloud valuation is low. Coreweave is an AI trading stock for now, and it is hard to take a fundamental view given the 'limited free float,' adds Arete. Shares of Nebius are up 4%, or $1.46, to $40.85 in premarket trading while CoreWeave is down 5% to $155.72. Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See today's best-performing stocks on TipRanks >> Read More on CRWV: Disclaimer & DisclosureReport an Issue Notable open interest changes for June 5th Nebius rallies after Arete picks over CoreWeave on valuation CoreWeave initiated with a Neutral at Arete Closing Bell Movers: MongoDB jumps 14% on earnings beat and raise Nvidia Stock (NVDA) Takes Battle to DeepSeek as AI Chips Go Full Speed Ahead Sign in to access your portfolio
Yahoo
28 minutes ago
- Yahoo
Harmony Biosciences settles generic drug litigation, strengthens patent
Harmony Biosciences (HRMY) announced a settlement agreement with Lupin Limited, resolving patent infringement litigation related to Lupin's Abbreviated New Drug Application for a generic version of WAKIX. Under the agreement, Lupin will receive a license to launch its generic product no earlier than January 2030 (or July 2030 with pediatric exclusivity), or earlier under certain circumstances. Harmony asserted multiple patents covering WAKIX, its FDA-approved treatment for excessive daytime sleepiness or cataplexy in adults and pediatric patients with narcolepsy. Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See the top stocks recommended by analysts >> Read More on HRMY: Disclaimer & DisclosureReport an Issue Harmony Biosciences Settles Patent Dispute with Lupin Harmony Biosciences assumed with an Outperform at Oppenheimer Harmony Biosciences Holds 2025 Annual Stockholders Meeting Harmony Biosciences price target raised to $48 from $44 at Mizuho Harmony Biosciences Holdings: Strong Market Position and Growth Potential Justify Buy Rating Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
34 minutes ago
- Yahoo
Life Time Group announces pricing of 20M share offering of common stock
Life Time Group (LTH) announced the pricing of the previously announced underwritten secondary offering of 20M shares of the company's common stock by certain selling stockholders, resulting in total gross proceeds of $590M, before deducting underwriting discounts and commissions. The offering is expected to close on June 6, 2025, subject to the satisfaction of customary closing conditions. The selling stockholders will receive all of the proceeds from the proposed offering. The company will not receive any of the proceeds from the sale of shares of the company's common stock by the selling stockholders. J.P. Morgan and BofA Securities are serving as the underwriters for the proposed offering. Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See Insiders' Hot Stocks on TipRanks >> Read More on LTH: Disclaimer & DisclosureReport an Issue Life Time Group announces 20M share offering of common stock for holders Life Time Group Holdings: Strategic Initiatives and Financial Performance Drive Buy Rating with $45 Price Objective Life Time Group assumed with a Buy at Craig-Hallum Life Time Group price target raised to $41 from $39 at Northland Life Time Group Holdings Reports Strong Q1 2025 Results Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
